Craig-Hallum Initiates Coverage On scPharmaceuticals with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker has initiated coverage on scPharmaceuticals (NASDAQ:SCPH) with a Buy rating and a price target of $20.
September 07, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
scPharmaceuticals has been initiated with a Buy rating by Craig-Hallum, with a price target of $20.
The initiation of coverage by Craig-Hallum with a Buy rating and a price target of $20 indicates a positive outlook for scPharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100